REFERENCES
- Sambrook P, Cooper C. Osteoporosis. Lancet. 2006;367(9527):2010–2018, review.
- Chatterjee RGM, Helal MA. Hypogonadism is a key contributor to the severity of osteoporosis in thalassaemic patients. 10th International Federation Conference (TIF) October 18–21; 2001.
- Chatterjee R, Katz M. Reversible hypogonadotrophic hypogonadism in sexually infantile male thalassaemic patients with transfusional iron overload. Clin Endocrinol (Oxf). 2000;53(1):33–42.
- Borgna-Pignatti C. Thalassemia. A few new tiles in a large mosaic. Haematologica. 2006;91(9):1159–1161, review.
- Chan YL, Pang LM, Chik KW, Cheng JC, Li CK. Patterns of bone diseases in transfusion-dependent homozygous thalassaemia major: predominance of osteoporosis and desferrioxamine-induced bone dysplasia. Pediatr Radiol. 2002;32:492–497.
- Morabito N, Gaudio A, Lasco A, et al. Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle. J Bone Miner Res. 2004;19:722–727.
- Voskaridou E, Terpos E, Spina G, et al. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Br J Haematol. 2003;123:730–737.
- Lasco A, Morabito N, Gaudio A, Buemi M, Wasniewska M, Frisina N. Effects of hormonal replacement therapy on bone metabolism in young adults with beta-thalassemia major. Osteoporos Int. 2001;12:570–575.